Taiho Completes Rolling NDA For TAS-102 In mCRC
This article was originally published in PharmAsia News
Executive Summary
Taiho has completed a rolling U.S. new drug application for its combination anticancer product TAS-102 for the treatment of refractory, metastatic colorectal cancer (mCRC), but the product will face a competitive market if approved.